Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.
PMID 9703286 · PMC2063030 · British journal of cancer · 1998 · 6 claims · 4 setups
Paclitaxel/cisplatin therapy produces a higher positive response rate than cyclophosphamide/cisplatin therapy in advanced ovarian cancer
-
Full-text index only
A human tumor-immune organoid model of glioblastoma.
PMID 41505256 · PMC12969483 · Cell reports · 2026 · 8 claims · 8 setups
iHOTT is an autologous co-culture platform integrating patient-derived tumor cells and matched PBMCs within human cortical organoids
-
Full-text index only
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
PMID 41912809 · PMC13099643 · Nature medicine · 2026 · 7 claims · 8 setups
Quemliclustat combined with gemcitabine/nab-paclitaxel (G/nP) with or without zimberelimab has a safety profile consistent with G/nP alone across dose-escalation and dose-expansion phases
-
Full-text index only
Nutritional genomics, polyphenols, diets, and their impact on dietetics.
PMID 18954579 · PMC2692306 · Journal of the American Dietetic Association · 2008 · 8 claims · 8 setups
Nutrient-gene interactions, exemplified by the MTHFR C677T polymorphism, modulate individual metabolic responses (e.g., homocysteine metabolism) and can be offset by adjusting nutrient intake such as folate
-
Full-text index only
Highlights of international conference of immunogenomics and immunomics, October 8-12, 2006 Budapest, Hungary.
PMID 17470366 · PMC7130317 · Cellular immunology · 2006 · 8 claims · 8 setups
An 'immunological constant of rejection' involving interferon-stimulated genes (ISGs) and innate immune effector functions (IEF) underlies diverse immune-mediated tissue destruction processes (allograft rejection, cancer rejection, autoimmunity, infection)